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Abstract 
In the last decade, significant advances have been 
made in Glioblastoma Multiforme treatment with the 
novel use of alternating electrical fields, also termed 
as tumour treating fields (TTFs). This modality has 
shown promising results in recurrent and newly 
diagnosed GBM patients, and according to some, may 
soon be considered an addition to the previously 
known 'trifecta' of GBM standard of care, i.e., surgery, 
chemo and radiation therapy.Here we review the 
existing data on TTF for both recurrent and newly 
diagnosed GBM. This review does not discuss the 
limitations of TTF, especially from compliance and 
cost point of view. 
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Introduction 
In the first in vivo study involving Tumour Treating 
Fields (TTF) was tested in ten patients with recurrent 
GBMs using non-invasive transducer arrays attached to 
the scalp, with significant improvement noted in time 
to tumour progression (TTP) [26.1 vs 9.5 weeks], 
progression free survival (PFS) at 6 months [50% vs 
15.3%,], and overall survival (OS) [median 62.2 vs 29.3 
weeks], without any systemic toxicity.1 In 2009, the 
same group performed a second pilot trial to 
understand the efficacy of TTFs in newly diagnosed 
patients in combination with standard adjuvant TMZ, 
and again noted very promising results (Median PFS 
[155 vs 31 weeks] and improved median OS [> 39 vs 
14.7 months]).2 
Review of Evidence 
We queried the PubMed database with the phrases 
'tumour treating fields in glioblastoma' and 
'alternating electric fields in brain tumours'. 
Abstracts of articles describing this treatment 
modality were reviewed. Articles addressing use of 
tumour treating fields in high grade gliomas were 
reviewed.  
Role in Recurrent GBM 
Median time to recurrence for GBMis approximately 
seven months and median survival 15-18 months. 
Repeat craniotomy and Bevacizumab have shown to 
be beneficial in the recurrent setting.3 Despite this, 
about 60% of patients relapse on Bevacizumab, can 
have serious side effects, develop resistance to the 
drug, and also fail to respond to any further 
chemotherapy.4 
In 2012, Stupp et al published their results on the first 
Phase III trial of 237 patients studying the effects of 
TTFs alone, compared with standard chemotherapy 
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Figure: An example of TTF applied on a patient.13
regimens in recurrent GBM.5 Thirty-six patients 
received bevacizumab, 36 received nitrosureas, 12 
received temozolomide, and 33 received other 
agents. It was noted that TTFs alone were comparably 
effective and had lower toxicity profile and better 
quality of life. This landmark study led to the FDA 
approval of NovoTTF-100A™ System (Novocure, Ltd., 
Haifa, Israel) as stand alone treatment for recurrent 
GBMs. Subsequently several post-hoc analyses of this 
trial were conducted which showed subsets of 
patients in whom TTFs alone resulted in improved OS 
compared to second line chemotherapy (11.8 vs 9.2 
months).6 Rulesh et al, in 2012, published their series 
of twenty patients with recurrent GBM who had been 
treated with TTFs between 2004 and 2007.7 They 
reported four long term survivors who were still alive 
at the time of publication. According to the authors, 
this was the first clinical study to have looked at the 
use of TTFs in recurrent GBM. However, the data 
reported on the original patients was quite limited 
and molecular characteristics of tumours in the 
survivors were not elucidated, hence not many 
conclusions can be drawn from it. Two trials are 
currently for recurrent GBM refractory to 
bevacizumab, and bevacizumab naive recurrent 
GBM.8,9 
Role in Newly Diagnosed GBM 
Stupp et al published their first randomized control trial 
on this subject in 2015.10 In this study, they used TTFs in 
combination with maintenance TMZ and compared this 
group with standard TMZ administration. 695 patients 
from 83 centers across the world were included 
between July 2009 and November 2014. Significant 
improvement in progression free survival and overall 
survival was noted: 7.1 months (95% CI, 5.9-8.2 months) 
in the TTF plus TMZ group and 4 months (95% CI, 3.3-5.2 
months) in the TMZ alone group. P= 0.001. Median 
overall survival was 20.5 months (95% CI, 16.7-25.0 
months) in the TTF plus TMZ group and 15.6 months 
(95%CI, 13.3-19.1 months) in the TMZ group P= 0.004). 
Given this improvement in survival, it has been 
suggested to include this as part of standard of care for 
newly diagnosed GBM, in addition to the Stupp 
Protocol.11 
In non-methylated MGMT promoter, TMZ is not 
considered a treatment option due to its resistance. A 
recent study by Clark et al effectively showed the 
utility of TTFs in both methylated and non-
methylated cells.12 As such, in patients with non-
methylated MGMT promoter, the application of TTFs 
after radiation should be effective. It is also 
interesting to note that tumour cells may develop 
some resistance to TTFs.  
Conclusion 
The introduction and popularization of tumour 
treating fields is a remarkable development in GBM 
treatment since the introduction of the Stupp protocol 
in 2005. It offers an entirely new area for research and 
possible options for treatment. So far, studies have 
shown promising results with this treatment modality, 
with the added benefit of minimal toxicity and 
improved quality of life compared to standard 
chemoradiation options.  
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